InspireMD (NSPR)
InspireMD on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
81K
Short interest
settlement 2026-10-15
1.0
Days to cover
unchanged vs prior
47.4%
Short share of volume
2026-11-02
8,426
Fails to deliver
settlement 2026-10-14
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NSPR is 80,900 shares, up 55,536 shares over the last month. Over the last 48 readings it ranged from 18,004 shares (29 May 2026) to 375,897 shares (15 July 2025). At the reported average volume of 150K shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nspr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 80,900 | +260.1% | 150,407 | 1.00 |
| 2026-09-30 | 22,466 | -11.4% | 70,548 | 1.00 |
| 2026-09-15 | 25,364 | -34.8% | 41,419 | 1.00 |
| 2026-08-31 | 38,879 | -54.4% | 106,585 | 1.00 |
| 2026-08-14 | 85,336 | -2.2% | 102,980 | 1.00 |
| 2026-07-31 | 87,281 | +13.5% | 34,710 | 2.51 |
| 2026-07-15 | 76,873 | +3.2% | 85,596 | 1.00 |
| 2026-06-30 | 74,465 | +41.6% | 88,802 | 1.00 |
| 2026-06-15 | 52,595 | +192.1% | 186,339 | 1.00 |
| 2026-05-29 | 18,004 | -48.7% | 197,089 | 1.00 |
| 2026-05-15 | 35,122 | -16.4% | 1,229,927 | 1.00 |
| 2026-04-30 | 42,009 | +46.1% | 70,072 | 1.00 |
| 2026-04-15 | 28,756 | +5.2% | 41,929 | 1.00 |
| 2026-03-31 | 27,323 | +35.1% | 58,980 | 1.00 |
| 2026-03-13 | 20,223 | -36.0% | 33,770 | 1.00 |
| 2026-02-27 | 31,585 | -15.9% | 16,534 | 1.91 |
| 2026-02-13 | 37,577 | +26.5% | 17,907 | 2.10 |
| 2026-01-30 | 29,712 | -0.1% | 33,894 | 1.00 |
| 2026-01-15 | 29,736 | -16.1% | 34,955 | 1.00 |
| 2025-12-31 | 35,463 | -46.5% | 55,453 | 1.00 |
| 2025-12-15 | 66,231 | -28.8% | 63,277 | 1.05 |
| 2025-11-28 | 92,953 | +115.6% | 143,161 | 1.00 |
| 2025-11-14 | 43,116 | -63.4% | 258,545 | 1.00 |
| 2025-10-31 | 117,732 | +2.4% | 70,133 | 1.68 |
| 2025-10-15 | 114,950 | +0.6% | 69,918 | 1.64 |
| 2025-09-30 | 114,273 | -9.4% | 176,927 | 1.00 |
| 2025-09-15 | 126,104 | -0.9% | 40,298 | 3.13 |
| 2025-08-29 | 127,319 | -58.1% | 113,197 | 1.12 |
| 2025-08-15 | 304,031 | -3.4% | 89,200 | 3.41 |
| 2025-07-31 | 314,576 | -16.3% | 110,436 | 2.85 |
| 2025-07-15 | 375,897 | +17.2% | 101,826 | 3.69 |
| 2025-06-30 | 320,682 | +63.9% | 657,152 | 1.00 |
| 2025-06-13 | 195,681 | -4.4% | 51,407 | 3.81 |
| 2025-05-30 | 204,654 | +6.8% | 40,779 | 5.02 |
| 2025-05-15 | 191,672 | +5.8% | 62,005 | 3.09 |
| 2025-04-30 | 181,090 | -5.7% | 34,995 | 5.17 |
| 2025-04-15 | 191,929 | -20.1% | 43,909 | 4.37 |
| 2025-03-31 | 240,060 | +9.0% | 58,334 | 4.12 |
| 2025-03-14 | 220,314 | +4.5% | 70,738 | 3.11 |
| 2025-02-28 | 210,929 | +5.9% | 100,887 | 2.09 |
| 2025-02-14 | 199,095 | +13.6% | 44,739 | 4.45 |
| 2025-01-31 | 175,341 | +1.9% | 26,311 | 6.66 |
| 2025-01-15 | 172,112 | +0.8% | 32,997 | 5.22 |
| 2024-12-31 | 170,723 | -1.7% | 23,824 | 7.17 |
| 2024-12-13 | 173,645 | -0.8% | 35,137 | 4.94 |
| 2024-11-29 | 175,045 | -11.8% | 129,569 | 1.35 |
| 2024-11-15 | 198,522 | +149.4% | 50,015 | 3.97 |
| 2024-10-31 | 79,595 | +80.9% | 19,473 | 4.09 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of NSPR volume is 47.4%, up 1.2 points over the last five sessions. Over the last 30 readings it ranged from 10.4% (19 October 2026) to 74.2% (8 October 2026). The latest reading is in line with the 30-session average of 46.6%, on 410K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 194K | 410K | 47.4% | 265 |
| 2026-10-30 | 145K | 197K | 73.3% | 0 |
| 2026-10-29 | 83K | 134K | 61.8% | 0 |
| 2026-10-28 | 200K | 335K | 59.8% | 0 |
| 2026-10-27 | 91K | 199K | 45.9% | 0 |
| 2026-10-26 | 79K | 171K | 46.2% | 0 |
| 2026-10-23 | 46K | 92K | 50.1% | 123 |
| 2026-10-22 | 165K | 309K | 53.4% | 0 |
| 2026-10-21 | 261K | 602K | 43.3% | 0 |
| 2026-10-20 | 41K | 57K | 71.6% | 0 |
| 2026-10-19 | 8K | 75K | 10.4% | 0 |
| 2026-10-16 | 4K | 24K | 14.7% | 0 |
| 2026-10-15 | 10K | 33K | 30.1% | 0 |
| 2026-10-14 | 54K | 112K | 48.5% | 0 |
| 2026-10-13 | 38K | 60K | 63.6% | 0 |
| 2026-10-12 | 19K | 50K | 37.3% | 0 |
| 2026-10-09 | 116K | 228K | 51.0% | 0 |
| 2026-10-08 | 105K | 142K | 74.2% | 0 |
| 2026-10-07 | 71K | 96K | 73.7% | 22,714 |
| 2026-10-06 | 20K | 129K | 15.4% | 1,347 |
| 2026-10-05 | 28K | 86K | 32.6% | 0 |
| 2026-10-02 | 12K | 31K | 39.5% | 80 |
| 2026-10-01 | 14K | 39K | 36.2% | 1,291 |
| 2026-09-30 | 46K | 106K | 43.6% | 13,541 |
| 2026-09-29 | 24K | 97K | 24.6% | 5,233 |
| 2026-09-28 | 13K | 19K | 71.0% | 0 |
| 2026-09-25 | 17K | 47K | 36.8% | 0 |
| 2026-09-24 | 11K | 29K | 35.7% | 0 |
| 2026-09-23 | 6K | 13K | 43.6% | 0 |
| 2026-09-22 | 49K | 76K | 63.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in NSPR is 8,426 shares, unchanged over the last settlement date. Over the last 30 readings it ranged from 1,031 shares (4 September 2026) to 74,480 shares (2 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 8,426 | $0.50 | $4K |
| 2026-10-13 | 8,426 | $0.51 | $4K |
| 2026-10-09 | 8,426 | $0.48 | $4K |
| 2026-10-08 | 8,426 | $0.49 | $4K |
| 2026-10-07 | 8,426 | $0.53 | $4K |
| 2026-10-06 | 8,426 | $0.58 | $5K |
| 2026-10-05 | 8,426 | $0.62 | $5K |
| 2026-10-02 | 8,426 | $0.62 | $5K |
| 2026-10-01 | 8,426 | $0.67 | $6K |
| 2026-09-30 | 8,426 | $0.69 | $6K |
| 2026-09-29 | 8,426 | $0.69 | $6K |
| 2026-09-28 | 8,426 | $0.70 | $6K |
| 2026-09-25 | 8,426 | $0.70 | $6K |
| 2026-09-24 | 8,426 | $0.74 | $6K |
| 2026-09-23 | 8,426 | $0.76 | $6K |
| 2026-09-22 | 8,426 | $0.75 | $6K |
| 2026-09-21 | 9,337 | $0.77 | $7K |
| 2026-09-18 | 8,426 | $0.76 | $6K |
| 2026-09-17 | 8,750 | $0.77 | $7K |
| 2026-09-16 | 9,377 | $0.77 | $7K |
| 2026-09-15 | 8,426 | $0.81 | $7K |
| 2026-09-14 | 8,426 | $0.80 | $7K |
| 2026-09-11 | 8,426 | $0.78 | $7K |
| 2026-09-10 | 8,426 | $0.79 | $7K |
| 2026-09-04 | 1,031 | $0.86 | $887 |
| 2026-08-05 | 1,469 | $0.72 | $1K |
| 2026-08-04 | 6,189 | $0.68 | $4K |
| 2026-06-09 | 50,231 | $0.82 | $41K |
| 2026-06-03 | 74,480 | $1.01 | $75K |
| 2026-06-02 | 74,480 | $0.99 | $74K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for NSPR in the last 90 days. The most recent filings are listed below. Latest filing: Stuka Paul (Director) on 2026-05-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Stuka Paul | Director | Buy | 20K | $0.88 | $18K | 668K |
| 2026-05-19 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 23K | $1.01 | $23K | 1.1M |
| 2026-05-14 | Stuka Paul | Director | Buy | 5K | $1.15 | $6K | 648K |
| 2026-05-13 | Stuka Paul | Director | Buy | 10K | $1.16 | $12K | 643K |
| 2026-05-12 | Slosman Marvin | CEO and President | Buy | 21K | $1.20 | $25K | 3.6M |
| 2026-05-11 | Stuka Paul | Director | Buy | 10K | $1.19 | $12K | 633K |
| 2026-05-08 | Stuka Paul | Director | Buy | 66K | $1.16 | $76K | 623K |
| 2026-05-07 | Ward Scott R. | Director | Buy | 73K | $1.15 | $84K | 237K |
| 2026-05-07 | Stuka Paul | Director | Buy | 6K | $1.15 | $7K | 532K |
| 2026-05-07 | ROUBIN GARY S | Director | Buy | 90K | $1.18 | $106K | 834K |
| 2026-05-06 | Ward Scott R. | Director | Buy | 16K | $1.15 | $18K | 164K |
| 2026-05-06 | Stuka Paul | Director | Buy | 2K | $1.12 | $2K | 525K |
| 2026-02-02 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $1.60 | $3K | 1.1M |
| 2026-02-02 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 3K | $1.59 | $5K | 1.1M |
| 2026-01-30 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 3K | $1.63 | $5K | 1.1M |
| 2026-01-29 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 5K | $1.65 | $8K | 1.1M |
| 2026-01-28 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 12K | $1.65 | $20K | 1.1M |
| 2026-01-27 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 5K | $1.66 | $8K | 1.2M |
| 2026-01-22 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 8K | $1.57 | $13K | 1.2M |
| 2026-01-21 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 18K | $1.62 | $29K | 1.2M |
| 2026-01-20 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 3K | $1.59 | $5K | 1.2M |
| 2026-01-16 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $1.61 | $4K | 1.2M |
| 2026-01-15 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 3K | $1.58 | $5K | 1.2M |
| 2026-01-14 | Ward Scott R. | Director | Grant | 88K | $0.00 | $0 | 148K |
| 2026-01-14 | Tommasoli Andrea | Chief Operating Officer | Grant | 227K | $0.00 | $0 | 954K |
| 2026-01-14 | Stuka Paul | Director | Grant | 132K | $0.00 | $0 | 524K |
| 2026-01-14 | Slosman Marvin | CEO and President | Grant | 1.1M | $0.00 | $0 | 3.5M |
| 2026-01-14 | ROUBIN GARY S | Director | Grant | 88K | $0.00 | $0 | 744K |
| 2026-01-14 | Lawless Michael A | Chief Financial Officer | Grant | 227K | $0.00 | $0 | 692K |
| 2026-01-14 | Gleason Shane Thomas | Chief Commercial Officer | Grant | 453K | $0.00 | $0 | 1.2M |
| 2026-01-14 | Dearen Danny L. | Director | Grant | 44K | $0.00 | $0 | 102K |
| 2026-01-14 | COHEN RAYMOND W | Director | Grant | 44K | $0.00 | $0 | 92K |
| 2026-01-14 | BERMAN MICHAEL | Director | Grant | 88K | $0.00 | $0 | 353K |
| 2025-12-30 | Arnold Kathryn | Director | Grant | 56K | $0.00 | $0 | 303K |
| 2025-12-09 | Stuka Paul | Director | Buy | 3K | $1.81 | $5K | 392K |
| 2025-12-09 | Stuka Paul | Director | Buy | 5K | $1.81 | $9K | 392K |
| 2025-12-05 | Stuka Paul | Director | Buy | 5K | $1.86 | $9K | 389K |
| 2025-12-04 | Stuka Paul | Director | Buy | 10K | $1.85 | $19K | 384K |
| 2025-11-12 | Stuka Paul | Director | Buy | 13K | $1.62 | $22K | 374K |
| 2025-10-07 | ROUBIN GARY S | Director | Grant | 48K | $0.00 | $0 | 656K |
| 2025-09-15 | Kester Thomas J | Director | Grant | 38K | $0.00 | $0 | 459K |
| 2025-07-30 | ROUBIN GARY S | Director | Buy | 41K | $2.42 | $100K | 608K |
| 2025-07-30 | Kester Thomas J | Director | Buy | 31K | $2.42 | $75K | 421K |
| 2025-07-30 | Slosman Marvin | CEO and President | Buy | 10K | $2.42 | $25K | 2.4M |
| 2025-07-30 | Stuka Paul | Director | Buy | 21K | $2.42 | $50K | 444K |
| 2025-07-11 | Kester Thomas J | Director | Exercise (in or at the money) | 31K | $1.38 | $42K | 390K |
| 2025-07-01 | Stuka Paul | Director | Exercise (in or at the money) | 88K | $1.38 | $121K | 424K |
| 2025-06-29 | BERMAN MICHAEL | Director | Exercise (in or at the money) | 61K | $1.38 | $85K | 245K |
| 2025-06-25 | ROUBIN GARY S | Director | Exercise (in or at the money) | 31K | $1.38 | $42K | 567K |
| 2025-05-30 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 7K | $2.51 | $18K | 1.1M |
| 2025-05-29 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 4K | $2.51 | $9K | 1.1M |
| 2025-05-27 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $2.51 | $4K | 1.1M |
| 2025-05-23 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $2.51 | $6K | 1.1M |
| 2025-02-25 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 10K | $3.65 | $37K | 1.1M |
| 2025-02-04 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 5K | $2.46 | $13K | 1.1M |
| 2025-02-03 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 7K | $2.51 | $18K | 1.1M |
| 2025-01-31 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 10K | $2.55 | $25K | 1.1M |
| 2025-01-30 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $2.51 | $6K | 1.1M |
| 2025-01-29 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 4K | $2.46 | $9K | 1.1M |
| 2025-01-28 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 2K | $2.61 | $6K | 1.1M |
| 2025-01-27 | Gleason Shane Thomas | Chief Commercial Officer | Sell | 4K | $2.71 | $10K | 1.1M |
| 2025-01-07 | Ward Scott R. | Director | Grant | 16K | $0.00 | $0 | 60K |
| 2025-01-07 | Tommasoli Andrea | Chief Operating Officer | Grant | 233K | $0.00 | $0 | 728K |
| 2025-01-07 | ROUBIN GARY S | Director | Grant | 32K | $0.00 | $0 | 534K |
| 2025-01-07 | BERMAN MICHAEL | Director | Grant | 32K | $0.00 | $0 | 265K |
| 2025-01-07 | Verta Patrick | EVP Clinical/Medical Affairs | Grant | 83K | $0.00 | $0 | 312K |
| 2025-01-07 | Slosman Marvin | CEO and President | Grant | 558K | $0.00 | $0 | 2.4M |
| 2025-01-07 | Kester Thomas J | Director | Grant | 32K | $0.00 | $0 | 359K |
| 2025-01-07 | Gleason Shane Thomas | Chief Commercial Officer | Grant | 233K | $0.00 | $0 | 747K |
| 2025-01-07 | Arnold Kathryn | Director | Grant | 32K | $0.00 | $0 | 248K |
| 2025-01-07 | Shore Craig | CFO and CAO | Grant | 233K | $0.00 | $0 | 1.1M |
| 2025-01-07 | Stuka Paul | Director | Grant | 49K | $0.00 | $0 | 360K |
| 2024-06-24 | BERMAN MICHAEL | Director | Exercise (in or at the money) | 61K | $1.38 | $85K | 184K |
| 2024-06-05 | Stuka Paul | Director | Exercise (in or at the money) | 88K | $1.38 | $121K | 336K |
| 2024-05-28 | ROUBIN GARY S | Director | Exercise (in or at the money) | 31K | $1.38 | $42K | 502K |
| 2024-05-28 | Kester Thomas J | Director | Exercise (in or at the money) | 31K | $1.38 | $42K | 327K |
| 2024-01-23 | Slosman Marvin | CEO and President | Grant | 563K | $0.00 | $0 | 1.9M |
| 2024-01-23 | Arnold Kathryn | Director | Grant | 29K | $0.00 | $0 | 215K |
| 2024-01-23 | BERMAN MICHAEL | Director | Grant | 29K | $0.00 | $0 | 232K |
| 2024-01-23 | ROUBIN GARY S | Director | Grant | 29K | $0.00 | $0 | 471K |
| 2024-01-23 | Gleason Shane Thomas | Chief Commercial Officer | Grant | 239K | $0.00 | $0 | 514K |
| 2024-01-23 | Kester Thomas J | Director | Grant | 29K | $0.00 | $0 | 296K |
| 2024-01-23 | Shore Craig | CFO and CAO | Grant | 239K | $0.00 | $0 | 880K |
| 2024-01-23 | Verta Patrick | EVP Clinical/Medical Affairs | Grant | 86K | $0.00 | $0 | 228K |
| 2024-01-23 | Stuka Paul | Director | Grant | 44K | $0.00 | $0 | 312K |
| 2024-01-23 | Tommasoli Andrea | Chief Operating Officer | Grant | 239K | $0.00 | $0 | 495K |
| 2024-01-02 | Arnold Kathryn | Director | Grant | 2K | $0.00 | $0 | 186K |
| 2024-01-02 | BERMAN MICHAEL | Director | Grant | 4K | $0.00 | $0 | 203K |
| 2024-01-02 | ROUBIN GARY S | Director | Grant | 3K | $0.00 | $0 | 442K |
| 2024-01-02 | Kester Thomas J | Director | Grant | 3K | $0.00 | $0 | 267K |
| 2023-11-30 | ROUBIN GARY S | Director | Buy | 50K | $2.53 | $127K | 439K |
| 2023-10-02 | ROUBIN GARY S | Director | Grant | 3K | $0.00 | $0 | 389K |
| 2023-10-02 | Arnold Kathryn | Director | Grant | 1K | $0.00 | $0 | 184K |
| 2023-10-02 | Kester Thomas J | Director | Grant | 3K | $0.00 | $0 | 264K |
| 2023-10-02 | BERMAN MICHAEL | Director | Grant | 3K | $0.00 | $0 | 199K |
| 2023-08-28 | Gleason Shane Thomas | Chief Commercial Officer | Grant | 19K | $0.00 | $0 | 276K |
| 2023-07-01 | Arnold Kathryn | Director | Grant | 2K | $0.00 | $0 | 183K |
| 2023-07-01 | Kester Thomas J | Director | Grant | 3K | $0.00 | $0 | 261K |
| 2023-07-01 | BERMAN MICHAEL | Director | Grant | 4K | $0.00 | $0 | 196K |
| 2023-07-01 | ROUBIN GARY S | Director | Grant | 3K | $0.00 | $0 | 386K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON19 holders report 5% or more of NSPR in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Daniel Mack at 10.0% of the class (4,819,647 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 5 | Daniel Mackparent holding company | 4.8M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Wilmot B. Harkeyparent holding company | 4.8M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Nantahala Capital Management, LLCinvestment adviser | 4.8M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Velan Capital Master Fund LPpartnership | 2.3M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Velan Capital Holdings LLCother entity | 2.3M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Velan Capital Investment Management LPpartnership | 2.3M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Velan Capital Management LLCother entity | 2.3M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Morgan Adamindividual | 2.3M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Venkataraman Balajiindividual | 2.3M | 5.0% | 2026-03-31 |
| 2026-04-24 | 13D | Marvin Slosmanindividual | 2.6M | 5.2% | 2026-01-22 |
| 2026-02-17 | 13G | ORBIMED ADVISORS LLCinvestment adviser | 3.1M | 7.4% | 2025-12-31 |
| 2026-02-17 | 13G | OrbiMed Capital GP IX LLCother entity | 2.9M | 6.8% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 9 | Rosalind Advisors, Inc.corporation | 11.0M | 9.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 9 | SALAMON STEVEN A Jindividual | 11.0M | 9.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 9 | Aharon Gilindividual | 11.0M | 9.2% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 9 | Rosalind Master Fund L.P.partnership | 9.5M | 8.3% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 9 | Rosalind Opportunities Fund I L.P.partnership | 1.5M | 1.0% | 2025-12-31 |
| 2026-02-02 | 13G/Ano. 1 | Aberdeen Group plcparent holding company | 3.2M | 7.5% | 2025-12-31 |
| 2026-02-02 | 13G/Ano. 1 | abrdn Inc.corporation, investment adviser | 3.2M | 7.5% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIPpartnership | 2.4M | 5.7% | 2025-09-30 |
| 2025-11-14 | 13G | Parkman Healthcare Partners LLCinvestment adviser, other entity | 2.4M | 5.8% | 2025-09-30 |
| 2025-11-14 | 13G | Parkman Healthcare Partners Holdings LPparent holding company, partnership | 2.4M | 5.8% | 2025-09-30 |
| 2025-11-14 | 13G | Parkman Healthcare Partners Holdings GP LLCparent holding company, other entity | 2.4M | 5.8% | 2025-09-30 |
| 2025-11-14 | 13G | Martinez Gregoryparent holding company, individual | 2.4M | 5.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | MARSHALL WACE, LLPinvestment adviser, partnership | 28.1M | 10.0% | 2025-09-30 |
| 2025-10-29 | 13D/Ano. 1 | Craig Shoreindividual | 1.5M | 3.5% | 2025-06-26 |
| 2025-10-29 | 13D | Michael A. Lawlessindividual | 3.6M | 8.6% | 2025-06-26 |
13F holders
Tracked managers holding NSPR at their latest 13F. JSON2 of the 30 tracked managers held NSPR at their latest 13F, $105K in total at quarter-end prices. Renaissance Technologies is the largest at $79K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 113K | $79K | 0.00% | +95K |
| Millennium Management | 2026-06-30 | 38K | $26K | 0.00% | -75K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) InspireMD reported revenue of $1.8M, down 0.4% from the same quarter a year earlier, and net loss of $14.3M (-0.17 diluted EPS). In FY 2025 it generated -$35.1M of operating cash flow.
- Cash
- $15.1M
- Equity
- $31.5M
- Total assets
- $44.6M
- Shares outstanding
- 46,489,118
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $1.8M | -$14.3M | -808.8% | -0.17 |
| Q1 FY 2026 | 2026-03-31 | $3.4M | -$13.7M | -402.9% | -0.16 |
| Q4 FY 2025derived | 2025-12-31 | $3.1M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $2.5M | -$12.7M | -503.7% | -0.17 |
| Q2 FY 2025 | 2025-06-30 | $1.8M | -$13.2M | -739.7% | -0.26 |
| Q1 FY 2025 | 2025-03-31 | $1.5M | -$11.2M | -730.3% | 0.22 |
| Q4 FY 2024derived | 2024-12-31 | $1.9M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $1.8M | -$7.9M | -435.9% | -0.16 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $9.0M | -$48.8M | -$35.1M | $1.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $7.0M | -$32.0M | -$21.9M | $1.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | $6.2M | -$19.9M | -$16.4M | $381K | n/a | n/a |
| FY 2022 | 2022-12-31 | $5.2M | -$18.5M | -$15.5M | $473K | n/a | n/a |
| FY 2021 | 2021-12-31 | $4.5M | -$14.9M | -$13.2M | $344K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-14 from the cover page.
What this page is
InspireMD in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows InspireMD (NSPR), SEC CIK 1433607, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-17.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-05-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1433607Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of NSPR is sold short?
80,900 shares were held short at the 2026-10-15 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NSPR's daily short volume?
On 2026-11-02, 194,209 of the 409,809 NSPR shares reported to FINRA were sold short, 47.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NSPR have fails to deliver?
The SEC's latest file shows 8,426 NSPR shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are NSPR insiders buying or selling?
No open-market insider trades were reported for NSPR in the last 90 days. The most recent filings are listed below. Latest filing: Stuka Paul (Director) on 2026-05-27.
Who owns 5% or more of NSPR?
19 holders report 5% or more of NSPR in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Daniel Mack at 10.0% of the class (4,819,647 shares), filed 2026-05-15 for an event on 2026-03-31.
What did NSPR report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) InspireMD reported revenue of $1.8M, down 0.4% from the same quarter a year earlier, and net loss of $14.3M (-0.17 diluted EPS). In FY 2025 it generated -$35.1M of operating cash flow.
Which tracked 13F managers own NSPR?
2 of the 30 tracked 13F managers held NSPR shares at their latest filing, $105K in all. The largest: Renaissance Technologies (113K shares, $79K), Izzy Englander's Millennium Management (38K shares, $26K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.